NASDAQ · MNKD
Healthcare · Biotechnology
$3.50
Down-$0.01 (-0.29%)
Updated Oct 30, 2026, 3:10 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MNKD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
MNKD closed at $3.50 after 21 trading sessions, down 11.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $3.49 | $3.57 | $3.48 | $3.50 | 2.28M |
| Oct 28, 2026 | $3.26 | $3.465 | $3.235 | $3.43 | 3.08M |
| Oct 27, 2026 | $3.23 | $3.30 | $3.17 | $3.29 | 2.51M |
| Oct 26, 2026 | $3.21 | $3.275 | $3.15 | $3.23 | 1.98M |
| Oct 23, 2026 | $3.18 | $3.205 | $3.09 | $3.19 | 3.09M |
| Oct 22, 2026 | $3.03 | $3.21 | $3.01 | $3.20 | 3.25M |
| Oct 21, 2026 | $3.10 | $3.13 | $3.04 | $3.05 | 2.8M |
| Oct 20, 2026 | $3.11 | $3.18 | $3.08 | $3.10 | 2.17M |
| Oct 19, 2026 | $3.18 | $3.22 | $3.07 | $3.09 | 2.46M |
| Oct 16, 2026 | $3.20 | $3.24 | $3.02 | $3.04 | 2.61M |
| Oct 15, 2026 | $3.02 | $3.20 | $2.995 | $3.19 | 3.76M |
| Oct 14, 2026 | $3.00 | $3.125 | $2.895 | $3.02 | 7.94M |
| Oct 13, 2026 | $3.13 | $3.14 | $3.02 | $3.05 | 4.39M |
| Oct 12, 2026 | $3.24 | $3.27 | $3.075 | $3.13 | 3.96M |
| Oct 9, 2026 | $3.40 | $3.405 | $3.23 | $3.29 | 4.55M |
| Oct 8, 2026 | $3.42 | $3.53 | $3.33 | $3.42 | 4.54M |
| Oct 7, 2026 | $3.67 | $3.676 | $3.39 | $3.45 | 6.01M |
| Oct 6, 2026 | $3.86 | $3.86 | $3.69 | $3.71 | 3.07M |
| Oct 5, 2026 | $3.82 | $3.85 | $3.70 | $3.82 | 2.88M |
| Oct 2, 2026 | $4.01 | $4.01 | $3.705 | $3.80 | 4.61M |
| Oct 1, 2026 | $3.84 | $4.225 | $3.83 | $3.95 | 10.19M |
The latest Smart Investors Daily articles mentioning MNKD.
Company
Market Activity
Research & News
MNKD research
Company profile and research snapshot.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 19, 2026 | Chardan Capital | Buy | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
| Sep 11, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 20, 2026
MannKind (NASDAQ:MNKD) Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and tolerability results that did not show the gastrointestinal issues often assoc
Benzinga · Oct 20, 2026
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
Yahoo · Oct 20, 2026
MannKind reported new clinical data for Furoscix ReadyFlow, showing IV-equivalent exposure and diuretic effect across thigh and upper arm injection sites in adults with heart failure or chronic kidney disease, following U.S. FDA approval in July 2026. The data suggests Furoscix ReadyFlow could help shift part of fluid overload care into outpatient settings, which may influence how MannKind allocates spending between commercialization, manufacturing capacity, and future Technosphere...
Benzinga · Oct 19, 2026
Chardan Capital analyst Andreas Argyrides initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $10.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MNKD.
